Equities research analysts expect that Alder BioPharmaceuticals (NASDAQ:ALDR) will report earnings of ($1.16) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.37) and the highest estimate coming in at ($1.04). Alder BioPharmaceuticals reported earnings of ($1.48) per share during the same quarter last year, which would indicate a positive year over year growth rate of 21.6%. The business is expected to report its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Alder BioPharmaceuticals will report full year earnings of ($4.92) per share for the current fiscal year, with EPS estimates ranging from ($5.82) to ($4.05). For the next year, analysts anticipate that the business will report earnings of ($3.73) per share, with EPS estimates ranging from ($5.46) to ($2.30). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Alder BioPharmaceuticals.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.50).
A number of analysts have recently issued reports on ALDR shares. Mizuho restated a “buy” rating and set a $29.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, January 31st. Goldman Sachs started coverage on Alder BioPharmaceuticals in a research report on Tuesday, April 24th. They set a “neutral” rating and a $17.00 price objective on the stock. ValuEngine cut Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Cowen set a $23.00 price objective on Alder BioPharmaceuticals and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, BidaskClub upgraded Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $26.77.
ALDR opened at $15.05 on Friday. The company has a market cap of $1.02 billion, a PE ratio of -3.04 and a beta of 2.52. The company has a current ratio of 13.31, a quick ratio of 13.30 and a debt-to-equity ratio of 0.57. Alder BioPharmaceuticals has a 1 year low of $8.60 and a 1 year high of $20.00.
In other Alder BioPharmaceuticals news, insider Jeffrey T. L. Smith sold 12,161 shares of the company’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $15.03, for a total value of $182,779.83. Following the sale, the insider now directly owns 5,871 shares in the company, valued at $88,241.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.60% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Flinton Capital Management LLC acquired a new position in Alder BioPharmaceuticals in the first quarter worth $100,000. Neuburgh Advisers LLC acquired a new position in Alder BioPharmaceuticals in the first quarter worth $121,000. Xact Kapitalforvaltning AB acquired a new position in Alder BioPharmaceuticals in the first quarter worth $142,000. SG Americas Securities LLC acquired a new position in Alder BioPharmaceuticals in the fourth quarter worth $132,000. Finally, Shepherd Kaplan Krochuk LLC acquired a new position in Alder BioPharmaceuticals in the first quarter worth $151,000.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.